Biodegradable nanoparticles as theranostics of ovarian cancer: an overview

Objectives Above 10 million people are suffering from cancers every year. As per American Cancer Society, more than 22 440 new cases and 14 080 deaths were reported from ovarian cancer yearly worldwide. This review explores the current status, challenges and future perspectives of tumour‐targeted th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy and pharmacology 2018-04, Vol.70 (4), p.435-449
Main Authors: Chaurasiya, Swati, Mishra, Vijay
Format: Article
Language:English
Subjects:
Animals
Biodegradability
biodegradable nanoparticles
Biodegradation
Clinical Trials as Topic - methods
Drug Carriers - administration & dosage
Drug Carriers - metabolism
Female
Humans
Nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - metabolism
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - metabolism
Precision medicine
Theranostic Nanomedicine - methods
theranostics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Above 10 million people are suffering from cancers every year. As per American Cancer Society, more than 22 440 new cases and 14 080 deaths were reported from ovarian cancer yearly worldwide. This review explores the current status, challenges and future perspectives of tumour‐targeted theranostic nanoparticles (NPs). Key findings Most of the ovarian malignancy cases are uncovered after the disease is in a difficult state due to poor screening techniques and non‐specific symptoms. In this manner, forceful and fruitful treatment is required that will indicate insignificant lethal impacts to solid tissue. In the current research, stealth biodegradable NPs are produced as vehicles for imaging and treatment of ovarian cancer as the controlled and targeted delivery of chemotherapeutic as well as imaging agents. To enhance the dependability of the colloidal suspension as well as to increase their circulation lifetime, NPs are introduced by incorporating the functional poly(ethylene glycol) on their surface, which also provides a site to conjugation of focusing on agents to ovarian tissue. Summary Biodegradable theranostic NPs can be fabricated and surface engineered without any alteration in drug‐loading capacity, safety and efficacy. These NPs have shown promising results in imaging as well as treatment of ovarian cancer.
ISSN:0022-3573
2042-7158
DOI:10.1111/jphp.12860